A physician may consider tirzepatide for patients who need medical support for obesity, overweight with weight-related health concerns, insulin resistance, blood sugar concerns, appetite control, or metabolic risk
12 mg: -24.2% body weight at 48 weeks
Recent studies show that GLP-1(936) can activate the inhibitory G protein (Gi/o), leading to the translocation of secretory granules (SG) beneath the cell membrane, thereby inhibiting glucagon secretion
Additionally, the limited supply of many of these products has increasingly shifted toward use in obesity treatment, driven by profit motives, leaving many type 2 diabetes patients unable to access medications they rely upon
Food-related social activities became less centered on eating itself, with participants noting ability to socialize without excessive food consumption